August 2018 Issue Table Of Contents

From The Editor

• Is Biopharma Ready For AI?

Feature Articles

• Readying Sanofi For The Era Of Digital Health
• Fibrocell: Where Gene Therapy Meets Synthetic Biology
• Alexis Howerton On Starting Up From New Science
• How To Broker Strategic Alliances Between International Biopharma Stakeholders

Capitol Perspectives

• Reviving The Antibiotic Sector

Patient Perspectives

• A Sense Of Urgency — It Goes Beyond Just Drug Development

CEO Corner

• Key Considerations For Building A Fully Integrated Biopharmaceutical Company

From Principles and Policy to Execution

• Bold Healthcare Policies Deliver The Right To Life, Liberty And The Pursuit Of Happiness

Industry Research

• Choosing A Development-Stage eCOA/ePRO Provider

Companies To Watch

• Acceleron

Inside The Industry

• Biopharma Startups Seek Big Pharma Expertise
• Mitigating Risks In Countries With Poor IP Protection
• Samsung Bioepis: Applying The “Hunger” For Biosimilars To Novel Drugs
• French Bioclusters Refocus Collaboration Efforts

Leadership Lessons

• Hidden Champion Leaders

Industry Leader

• As Pediatric Rare Disease Patients Grow Up, Can We Keep Pace?
• Why Soft Skills Are The Key To Better Science And Collaborations

Ask The Board

• When Do You Think BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In Clinical Research?
• What Are Pharma Companies Doing To Provide Greater Commitment To Ethical Practices And Transparencies Along With Corporate Social Responsibility?
• What Are The Socioeconomic Impacts Of Life-Span-Extending Medicines And Treatments? What Developments Are Really Promising?